Premium
Rivaroxaban (Xarelto) in the management of stroke and DVT
Author(s) -
Chaplin Steve,
Haunton Victoria,
Robinson Thompson,
Bagot Catherine
Publication year - 2012
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.950
Subject(s) - rivaroxaban , medicine , stroke (engine) , intensive care medicine , adverse effect , physical medicine and rehabilitation , warfarin , atrial fibrillation , mechanical engineering , engineering
Rivaroxaban is now licensed for the prevention of stroke and the treatment and prevention of DVT. In our New products review, Steve Chaplin presents the clinical data for its efficacy and adverse events related to these new indications, and specialists comment on its likely place in therapy.